EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

C Robert, G V Long, J Larkin, J D Wolchok, J C Hassel, D Schadendorf, F S Hodi, C Lebbé, J-J Grob, J R Hyngstrom, J Wagstaff, J Chesney und 9 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2024.115119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von C Robert und 20 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy and Paris-Saclay University, Villejuif-Paris Sud, France. Electronic address: caroline.robert@gustaveroussy.fr. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Melanoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the predictive value of RECIST response within 3, 6, or 12 months on long-term survival, and explore differences between nivolumab+ipilimumab and nivolumab monotherapy, we analyzed pooled 5-year data of 935 responder and non-responder patients at various time points after treatment initiation in CheckMate 069, 066, and 067 studies. PATIENTS AND METHODS: Treatment-naive advanced melanoma patients received nivolumab+ipilimumab or nivolumab monotherapy. To decrease immortal time bias, 3-, 6-, or 12-month overall survival (OS) and progression-free survival (PFS) landmark analyses were performed. Association between characteristics and response was evaluated by univariate and multivariate analyses. RESULTS: Response rates at any time were 58 % (239/409) for nivolumab+ipilimumab and 44 % (230/526) for nivolumab monotherapy. In 12-month landmark analyses, 5-year OS rates for responders versus non-responders were 82 % versus 40 % with nivolumab+ipilimumab (HR=0.23 [95 % CI, 0.15-0.35]) and 76 % versus 32 % with nivolumab monotherapy (HR=0.22 [95 % CI, 0.16-0.31]). PFS rates were 83 % versus 32 % and 69 % versus 46 %, respectively. Similar strong associations between response at 3 and 6 months and 5-year OS and PFS were also observed with more than 70 % of the responses observed in the first 3 months. Response rates correlated with baseline LDH and PD-L1 status by multivariate analysis but the association between response and long-term survival was maintained in landmark analyses even among patients with high LDH and low PD-L1 expression. CONCLUSION: Clinical response evaluated in the first months of therapy is a strong predictor of long-term survival, even in patients with poor prognostic biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabIpilimumabMelanomaAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedAdultProgression-Free SurvivalTime FactorsTreatment OutcomeSkin NeoplasmsAged, 80 and over

Stichwörter der Autor:innen

Advanced melanomaClinical responseIpilimumabLong-term survivalNivolumabPrognostic factors

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Gustave Roussy and Paris-Saclay University, Villejuif-Paris Sud, France. Electronic address: caroline.robert@gustaveroussy.fr.
  • Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
  • Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Meyer Cancer Center, Weill Cornell Medical College, New York, NY, USA.
  • Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germa…
  • University Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, Germany & National Center for Tumor Diseases (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Cen…

Förderung

  • NCI NIH HHS

Zitieren

APA

Robert, C., Long, G. V., Larkin, J., Wolchok, J. D., Hassel, J. C., Schadendorf, D., Hodi, F. S., Lebbé, C., Grob, J. J., Hyngstrom, J. R., Wagstaff, J., Chesney, J., Butler, M. O., Bechter, O., Márquez-Rodas, I., Pavlick, A. C., Durani, P., Pe Benito, M., Wang, P., …, & Ascierto, P. A. (2025). Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115119

Vancouver

Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, et al. Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2024.115119

BibTeX
@article{Robert2025,
  author = {Robert, C and Long, G V and Larkin, J and Wolchok, J D and Hassel, J C and Schadendorf, D and Hodi, F S and Lebbé, C and Grob, J-J and Hyngstrom, J R and Wagstaff, J and Chesney, J and Butler, M O and Bechter, O and Márquez-Rodas, I and Pavlick, A C and Durani, P and Pe Benito, M and Wang, P and Postow, M A and Ascierto, P A},
  title = {Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2024.115119}
}
Kostenlos starten →